Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease A Mendelian Randomization Analysis by Ference, Brian A. et al.
M
C
D
i
M
H
r
a
Journal of the American College of Cardiology Vol. 60, No. 25, 2012
© 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
PCardiometabolic Risk
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Objectives The purpose of this study was to estimate the effect of long-term exposure to lower plasma low-density lipopro-
tein cholesterol (LDL-C) on the risk of coronary heart disease (CHD).
Background LDL-C is causally related to the risk of CHD. However, the association between long-term exposure to lower
LDL-C beginning early in life and the risk of CHD has not been reliably quantified.
Methods We conducted a series of meta-analyses to estimate the effect of long-term exposure to lower LDL-C on the risk of
CHD mediated by 9 polymorphisms in 6 different genes. We then combined these Mendelian randomization studies
in a meta-analysis to obtain a more precise estimate of the effect of long-term exposure to lower LDL-C and compared it
with the clinical benefit associated with the samemagnitude of LDL-C reduction during treatment with a statin.
Results All 9 polymorphisms were associated with a highly consistent reduction in the risk of CHD per unit lower LDL-C,
with no evidence of heterogeneity of effect (I2  0.0%). In a meta-analysis combining nonoverlapping data from
312,321 participants, naturally random allocation to long-term exposure to lower LDL-C was associated with a
54.5% (95% confidence interval: 48.8% to 59.5%) reduction in the risk of CHD for each mmol/l (38.7 mg/dl)
lower LDL-C. This represents a 3-fold greater reduction in the risk of CHD per unit lower LDL-C than that ob-
served during treatment with a statin started later in life (p  8.43  1019).
Conclusions Prolonged exposure to lower LDL-C beginning early in life is associated with a substantially greater reduction in
the risk of CHD than the current practice of lowering LDL-C beginning later in life. (J Am Coll Cardiol 2012;60:
2631–9) © 2012 by the American College of Cardiology Foundation
ublished by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.017The causal relationship between low-density lipoprotein
cholesterol (LDL-C) and coronary atherosclerosis is well
established. Multiple randomized trials have demonstrated
that lowering LDL-C by treatment with a statin signifi-
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ccepted September 11, 2012.cantly reduces the risk of major coronary events (1). How-
ever, persons being treated with a statin continue to expe-
rience a substantial residual risk of events. Because coronary
atherosclerosis is a chronic, progressive disease that begins
early in life and develops slowly over several decades before
becoming clinically manifest, it is intuitively appealing to
See page 2640
hypothesize that lowering LDL-C beginning earlier in life
may prevent or substantially delay the progression of coro-
nary atherosclerosis and thereby significantly improve the
clinical benefit of therapies that lower LDL-C (2–4).
Although intuitive, the clinical benefit of lowering LDL-C
beginning early in life is unknown. Ideally, the effect of
long-term exposure to lower LDL-C on the risk of coronary
heart disease (CHD) would be evaluated in a randomized,
controlled trial. Unfortunately, the cost and logistical complex-
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ber of young asymptomatic people
over several decades within the
context of a clinical trial may be
impractical. However, in the ab-
sence of a randomized trial, it may
still be possible to estimate the
effect of random allocation to
long-term exposure to lower
LDL-C on the risk of CHD by
appealing to the principle of Men-
delian randomization.
Multiple single-nucleotide poly-
morphisms (SNPs) are associated
with small differences in LDL-C (5). Each of these poly-
morphisms is allocated randomly at the time of conception
in a process sometimes referred to as Mendelian random-
ization (6). Inheriting an allele associated with lower
LDL-C is therefore analogous to being randomly allocated
to a therapy that lowers LDL-C beginning at birth, whereas
inheriting the other allele is analogous to being randomly
allocated to usual care. If certain assumptions are satisfied
(6), then the association between such a polymorphism and
the risk of CHD should provide an unconfounded estimate
of the effect of lifelong exposure to lower LDL-C on the
risk of CHD in a manner analogous to a long-term
randomized trial comparing a therapy that lowers LDL-C
beginning early in life with usual care. For example, persons
who inherit a 46L allele of the PCSK9 gene have been
reported to have both lower lifelong exposure to LDL-C
Abbreviations
and Acronyms
CHD  coronary heart
disease
HDL-C  high-density
lipoprotein cholesterol
LDL-C  low-density
lipoprotein cholesterol
MI  myocardial infarction
OR  odds ratio
SNP  single-nucleotide
polymorphism
Figure 1 Association Between Exposure Alleles and LDL-C
Boxes represent the summary point estimate of effect for the association between ea
Bars represent 95% confidence interval (CI). SNP  single-nucleotide polymorphism.and a much greater than expected reduced risk of CHD (7).
Subsequent studies of this and other polymorphisms have
reported generally similar, although less dramatic, results
(8,9). However, the magnitude and consistency of the
association between long-term exposure to lower LDL-C
and the risk of CHD mediated by a variety of different
polymorphism has not been reliably quantified. A reliable
estimate of the association between long-term exposure to
lower LDL-C and the risk of CHD would provide impor-
tant information about whether the magnitude of this effect
is sufficiently compelling to influence public health policy,
professional guidelines, and individual treatment decisions.
Therefore, we conducted a series of meta-analyses to esti-
mate the association between lifelong exposure to lower
LDL-C and the risk of CHD mediated by 9 SNPs in 6
different genes. We then meta-analyzed the results of these
Mendelian randomization studies to reliably quantify the
effect of long-term exposure to lower LDL-C on the risk of
CHD and compared it with the effect of lowering LDL-C
during treatment with a statin started later in life.
Methods
Design and rationale. Our study consisted of several
interrelated components. First, we selected, a priori, 9 SNPs
located in 6 different genes (Fig. 1). Each of these polymor-
phisms has been previously reported to be associated with
LDL-C, but not to be reliably associated with other
lipoproteins or nonlipid risk factors for coronary disease (5).
e selected these SNPs specifically to minimize the poten-
osure allele and low-density lipoprotein cholesterol (LDL-C) measured in mmol/l.ch exp
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defined the exposure allele as the allele previously associated
with lower LDL-C. Second, we conducted a series of
meta-analyses to quantify the association between the ex-
posure allele for each SNP and circulating levels of LDL-C.
Third, we conducted a series of meta-analyses to quantify the
association between the exposure allele for each SNP and the
risk of CHD. Fourth, we standardized the association between
the exposure allele for each SNP and the risk of CHD per unit
lower LDL-C to directly compare the effect of long-term
exposure to lower LDL-C on the risk of CHD mediated by a
variety of different mechanisms. Fifth, we combined the effect
estimates for each exposure allele on the risk of CHD adjusted
per unit lower LDL-C in a meta-analysis to obtain a more
precise overall summary estimate of the effect of long-term
exposure to lower LDL-C on the risk of CHD. Sixth, we
compared the risk reduction associated with long-term expo-
sure to lower LDL-C estimated from the combined meta-
analysis of the genetic studies with the risk reduction associated
with the same magnitude of LDL-C reduction observed in a
meta-analysis of statin trials.
Contributing studies and data. We searched PubMed,
EMBASE, and Index of Science, as well as the supplemen-
tary materials, online data repositories, and references of
selected articles to identify all published and unpublished
data on the association between circulating levels of LDL-C
and each of the 9 SNPs included in our study. We then
conducted a similar search to identify all published and
unpublished data on the association between the risk of
Figure 2 Association Between Exposure Alleles and Risk of CH
Boxes represent the summary point estimate of odds ratio (OR) for the associatio
sent 95% CI. (Unlike the other SNPs, the APOE-C1-C2 SNP rs4420638 is associat
cifically to assess for heterogeneity of effect on the risk of CHD.) Abbreviations asCHD and each of the 9 SNPs. The primary outcome was
CHD, defined as a composite of cardiovascular death, nonfatal
myocardial infarction, or coronary revascularization as adopted
by the CARDIoGRAM consortium (10), or where this
onvention was not followed (or could not be extracted from
he available data), we used the individual study-specific
rimary outcome. To estimate the clinical benefit of lower-
ng LDL-C beginning later in life, we relied on data from
meta-analysis of statin trials conducted by the Cholesterol
reatment Trialists’ Collaboration (1).
tatistical analysis. All meta-analyses were performed us-
ng inverse-variance weighted fixed-effect models (sensitiv-
ty analyses were performed using random-effects models).
or each SNP, we standardized the estimate of the associ-
tion between the exposure allele and the risk of CHD per
nit lower LDL-C by dividing the natural log of the
ummary odds ratio (OR) and its SE by the effect estimate
or the association between that allele and LDL-C (using
he usual ratio of effect estimates method). We then
ombined the adjusted summary OR for each SNP in a
eta-analysis to more precisely estimate the effect of long-
erm exposure to lower LDL-C. Each SNP was prioritized
or inclusion in this meta-analysis by the inverse of the SE
f its summary point estimate of effect, adjusted per unit
ower LDL-C. Nonoverlapping data from studies evaluat-
ng each SNP were successively added to the meta-analysis
n order of the inverse SE ranking of the SNPs. We
erformed multiple sensitivity analyses by including non-
verlapping data from multiple different combinations of
een each exposure allele and risk of coronary heart disease (CHD). Bars repre-
h LDL-C, HDL-C, triglycerides, and C-reactive protein. We included this SNP spe-
ure 1.D
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Long-Term Reduction in LDL Cholesterol December 25, 2012:2631–9SNPs in the meta-analysis. To further investigate the effect
of long-term exposure to lower LDL-C on the risk of
CHD, we also constructed a weighted LDL-C genetic
score. As described elsewhere, regression on the risk score
can be reconstructed from the regressions of the individual
SNPs without access to individual level data (11). Further
details of this analysis are provided in Online Table 1.
Next, we standardized the results of each of the statin
trials per unit reduction in LDL-C using the same methods
as described for the genetic studies. We then compared the
risk reduction associated with long-term exposure to lower
LDL-C with the risk reduction associated with the same
magnitude of LDL-C reduction during treatment with a
statin using a z-test. Heterogeneity was assessed using
Cochran’s Q, and the I2 metric (12). To minimize the
otential for population stratification bias, we restricted all
nalyses to persons of European ancestry, and we used
enomic-control or principal component–adjusted measures
f effect where provided. Care was taken to avoid double-
ounting data from studies that were included in1 report. All
tatistical tests used a 2-sided   0.05 as the threshold for
tatistical significance, and all analyses were performed using
TATA (version 10.1, StataCorp, College Station, Texas).
esults
n separate meta-analyses involving sample sizes of up to 149,000
articipants, the exposure allele for each SNP was associated with
lower LDL-C level that varied significantly between 2.6 and
Figure 3 Log-Linear Effect of Each Unit Long-Term Exposure to
Boxes represent the proportional risk reduction (1  OR) of CHD for each exposur
allele (measured in mg/dl). Vertical lines represent 1 SE above and below the po
absolute magnitude of associations with lower LDL-C. The line (which is forced to
per unit lower long-term exposure to LDL-C. Abbreviations as in Figure 2.6.7 mg/dl among the included polymorphism (Fig. 1) (5,8,
3–27). Detailed results of these 9 meta-analyses are presented in
nline Figures 1a to 1i. In separate meta-analyses involving
ample sizes of up to 186,000 participants, the exposure allele for
ach SNP was also associated with a correspondingly lower risk of
HD (Fig. 2) (8–10,17,20,21,27–37). Detailed results of these 9
eta-analyses are presented in Online Figures 2a to 2i. There was
substantial amount of heterogeneity of effect on the risk of CHD
mong the included polymorphisms. The exposure alleles of the
ncluded SNPs were associated with a reduction in the risk CHD
hat varied significantly between 6% and 28% (I2  91.8%).
In a plot of the proportional risk reduction against the
magnitude of lower LDL-C associated with each exposure
allele, the relationship between long-term exposure to lower
LDL-C and the risk of CHD was approximately log-linear
(Fig. 3). After standardizing the effect of each exposure
allele per unit lower LDL-C, each SNP was associated with
a highly consistent effect on the risk of CHD (Table 1).
Indeed, after adjusting the effect of each SNP per unit lower
LDL-C, there was no evidence of any heterogeneity of
effect on the risk CHD among the included SNPs, with the
I2 metric being reduced from 91.8% to 0.0% (Fig. 4, Online
Fig. 3). In a meta-analysis of nonoverlapping data from
312,321 participants involving multiple different SNPs,
each mmol/l (38.7 mg/dl) lower long-term exposure to
LDL-C was associated with a 54.5% (OR: 0.46, 95% CI:
0.41 to 0.51; p  2.15  1045) reduction in the risk of
HD (Fig. 5). Detailed results of this meta-analysis are
r LDL-C on Risk of CHD
e plotted against the absolute magnitude of lower LDL-C associated with that
imate of proportional risk reduction. SNPs are plotted in order of increasing
hrough the origin) represents the increase in proportional risk reduction of CHDLowe
e allel
int est
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DW
e
o
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yses, this result did not change appreciably regardless of
which SNPs were included in the meta-analysis of nonover-
lapping data (Online Fig. 5). Furthermore, in a common
sample of up to 83,873 participants, a weighted LDL-C
genetic score composed of 6 SNPs (1 at each gene) was
associated with a similar 53.2% reduction in the risk of
CHD (OR: 0.47, 95% CI: 0.41 to 0.53; p  2.42  1032)
for each mmol/l lower LDL-C (Online Table 1).
In a meta-analysis of 169,138 participants enrolled in 26
statin trials, treatment with a statin was associated with a
24% reduction in the risk of CHD (OR: 0.76, 95% CI: 0.74
to 0.78) per mmol/l (38.7 mg/dl) reduction in LDL-C
Associations of Exposure Alleles With CHD Adjusted per Unit of ChTable 1 Associations of Exposure Alleles With CHD Adjusted p
SNP
Exposure
Allele Frequency
LDL Effect,
mmol/l (mg/dl)
Sample
Size ORCHD (95%
rs599839 0.22 0.16 (6.00) 141,565 0.88 (0.86–
rs646776 0.21 0.15 (5.71) 111,900 0.88 (0.86–
rs11206510 0.19 0.08 (2.93) 186,582 0.94 (0.92–
rs11591147 0.02 0.43 (16.68) 127,651 0.72 (0.62–
rs6511720 0.11 0.19 (7.50) 77,041 0.87 (0.83–
rs2228671 0.12 0.15 (5.70) 82,880 0.89 (0.86–
rs12916 0.61 0.07 (2.63) 49,160 0.94 (0.90–
rs4299376 0.70 0.07 (2.86) 118,842 0.94 (0.92–
rs4420638 0.83 0.18 (7.10) 75,487 0.86 (0.83–
Point estimates of effect adjusted per unit lower LDL-C obtained by dividing the natural logarithm
exposure allele measured in reference units (0.125, 0.25, 0.50, and 1.0 mmol/l, respectively), us
CHD  coronary heart disease; CI  confidence interval; LDL-C  low-density lipoprotein chole
Figure 4 Association of Exposure Alleles With Risk of CHD per
Unadjusted OR for the association between each exposure allele and the risk of C
Abbreviations as in Figures 1 and 2.(Online Table 2). Compared to treatment with a statin
started later in life, prolonged exposure to lower LDL-C
beginning early in life was associated with a 3-fold
greater reduction in the risk of CHD (on the log scale)
for each unit lower LDL-C (Fig. 5). This difference in
risk reduction per unit lower LDL was highly numerically
stable (p  8.4  1019).
iscussion
e sought to reliably quantify the effect of long-term
xposure to lower LDL-C beginning early in life on the risk
f CHD. To do this, we conducted a series of meta-analyses
in LDL-Cit of Change in LDL-C
ORCHD (95% CI) Adjusted per Unit Lower LDL
0.125 mmol/l
(4.83 mg/dl)
0.25 mmol/l
(9.67 mg/dl)
0.50 mmol/l
(19.33 mg/dl)
1.00 mmol/l
(38.67 mg/dl)
0.90 (0.89–0.92) 0.82 (0.79–0.85) 0.66 (0.62–0.72) 0.44 (0.38–0.52)
0.90 (0.88–0.93) 0.81 (0.77–0.86) 0.66 (0.59–0.74) 0.43 (0.35–0.54)
0.90 (0.87–0.93) 0.81 (0.76–0.86) 0.66 (0.58–0.74) 0.43 (0.34–0.54)
0.91 (0.87–0.95) 0.83 (0.76–0.91) 0.69 (0.58–0.82) 0.47 (0.33–0.67)
0.92 (0.89–0.95) 0.84 (0.78–0.90) 0.70 (0.61–0.81) 0.49 (0.38–0.65)
0.91 (0.88–0.94) 0.83 (0.77–0.89) 0.69 (0.60–0.79) 0.47 (0.36–0.62)
0.90 (0.83–0.97) 0.80 (0.69–0.93) 0.64 (0.47–0.87) 0.41 (0.22–0.76)
0.90 (0.86–0.94) 0.81 (0.75–0.88) 0.65 (0.56–0.77) 0.43 (0.31–0.59)
0.90 (0.88–0.93) 0.82 (0.78–0.86) 0.67 (0.60–0.74) 0.44 (0.36–0.54)
unadjusted OR (and its SE) for each exposure allele by the LDL-C effect size associated with that
ratio of effect estimates method.
NP  single-nucleotide polymorphism; OR  odds ratio.
Lower LDL-C
described in Figure 2, and after adjustment per 0.125 mmol/l lower LDL-C.angeer Un
CI)
0.90)
0.91)
0.96)
0.84)
0.92)
0.93)
0.98)
0.96)
0.89)
of theUnit
HD as
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lower LDL-C and the risk of CHD mediated by 9 SNPs in
6 different genes. For each SNP, we used the allele associ-
ated with lower LDL-C as a proxy for a treatment that
lowers LDL-C beginning at birth to estimate the effect of
lowering LDL-C beginning early in life. Because each SNP
is allocated randomly at the time of conception, the results
of these Mendelian randomization studies should be uncon-
founded by other lipid and nonlipid risk factors for CHD,
and therefore they can be thought of as approximately
analogous to a series of natural randomized trials evaluating
the effect of long-term exposure to lower LDL on the risk
of CHD. We then combined these Mendelian randomiza-
tion studies in a meta-analysis to obtain a more precise
estimate of the effect of long-term exposure to lower
LDL-C on the risk of CHD and compared it with the effect
of lowering LDL-C during treatment with a statin.
In a meta-analysis involving 312,00 participants, we
found that naturally random allocation to long-term expo-
sure to lower LDL-C beginning early in life was associated
with a 3-fold greater reduction in the risk of CHD for each
unit lower LDL-C than that observed during treatment
with a statin started later in life. For example, long-term
exposure to 1 mmol/l (38.7 mg/dl) lower LDL-C was
associated with a 55% reduction in the risk of CHD
(OR: 0.45). By contrast, treatment with a statin started
later in life would require a 3-fold greater reduction in
LDL-C of 3 mmol/l (116 mg/dl) to achieve this same
Figure 5 Comparative CHD Risk Reduction of Earlier and Later
Boxes represent the summary point estimate of the OR for the association betwe
from Mendelian randomization studies adjusted per unit lower LDL-C and meta-ana
Appendix for details. Abbreviations as in Figures 1 and 2magnitude of risk reduction (OR: 0.44 0.76 · 0.76 · 0.76).Furthermore, we found that the association between
long-term exposure to lower LDL-C and the risk of CHD
was approximately log-linear, just as the association between
the magnitude of LDL-C reduction and the clinical benefit
of statin therapy is approximately log-linear (38). Therefore,
if this log-linear relationship extends beyond the observed
range of data in our study, as it does for the association
between LDL-C and the risk of CHD in both epidemio-
logical studies (39) and in the statin trials, then prolonged
exposure to very low levels of LDL-C beginning early in life
could potentially result in dramatic reductions in the risk of
CHD. Indeed, the results of our study are consistent with
the observation that CHD appears to be rare in societies
that maintain very low levels of LDL-C throughout adult-
hood (40).
The magnitude of the effect of prolonged exposure to
lower LDL-C on the risk of CHD observed in our study
was also substantially greater than predicted based on the
results of observational epidemiological studies. For exam-
ple, the 55% reduction in the risk of CHD per mmol/l lower
long-term exposure to LDL-C observed in our study is
more than 2-fold greater (on the log scale) than the 31%
(OR: 0.69, 95% CI: 0.65 to 0.74) risk reduction per mmol/l
lower non-HDL cholesterol (and directly measured
LDL-C) observed in a large meta-analysis (39) of prospec-
tive cohort studies (p for difference  7.4  1010). This
finding suggests that genetically mediated changes in
LDL-C are likely to be a better reflection of the cumulative
C Lowering
h unit lower LDL-C and the risk of CHD, for both meta-analyses combining data
of statin trials adjusted per unit lower LDL-C. Bars represent 95% CI. See OnlineLDL-
en eac
lyseseffect of lifelong exposure to differences in circulating
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hood, even when those measurements are corrected for
regression dilution bias.
Importantly, we evaluated 9 polymorphisms located in 6
different genes, including polymorphisms in the genes that
encode for the targets of both statins and monoclonal
antibodies directed against PCSK9. Although each of these
polymorphisms presumably affects circulating LDL-C levels
by a different mechanism, and the per-allele effect of these
SNPs on LDL-C levels varied by more than 6-fold; all 9
polymorphisms were associated with a highly consistent
reduction in the risk of CHD when measured per unit lower
LDL-C. This finding suggests that the effect of long-term
exposure to lower LDL-C on the risk of CHD appears to be
independent of the mechanism by which LDL-C is low-
ered. Therefore, the method of lowering LDL-C is likely to
be less important than the magnitude and timing of LDL-C
reduction. As a result, diet and exercise are probably as
effective at reducing the risk of CHD as are statins or
other treatments that lower LDL-C when started early in
life (and when measured per unit lower LDL-C).
The results of our study support the hypothesis that
lowering LDL-C beginning early in life, or approximately
equivalently maintaining low levels of LDL-C throughout
life, may prevent or substantially delay the development of
atherosclerosis. Indeed, our study demonstrates that pro-
longed exposure to lower LDL-C beginning early in life,
before the development of atherosclerosis, is associated with
a substantially greater reduction in the risk of CHD than
the current practice of lowering LDL-C beginning later in
life after atherosclerosis has already developed. This finding
may explain much of the residual risk of coronary events
experienced by persons being treated with a statin or other
lipid-lowering therapy. Lowering LDL-C beginning later
in life after the development of atherosclerosis may serve
merely to stabilize existing atherosclerotic plaques that can
still progress to cause symptoms or disrupt to cause acute
coronary syndromes, thus resulting in a high residual risk of
events. By contrast, prolonged exposure to lower LDL-C
beginning early in life is associated with a substantially
greater reduction in the risk of CHD and therefore a
substantially lower corresponding residual risk of coronary
events.
The results of our study also suggest that lowering
LDL-C is likely to be a much more effective strategy for the
primary prevention of CHD than is currently recognized.
Current estimates of the effectiveness of lowering LDL-C
as a strategy for the primary prevention of CHD are based
largely on data from the statin trials. However, the mean age
at the time of randomization in the statin trials was 63 years
(1), which means that persons enrolled in these trials had
already been exposed to a lifetime of circulating LDL-C.
Our study demonstrates that both the magnitude of expo-
sure to LDL-C and the length of time exposed to LDL-C
each have an important effect on the risk of CHD. Therefore,
the effectiveness of lowering LDL-C as a strategy for theprimary prevention of CHD can potentially be substantially
improved by initiating therapies to lower LDL-C beginning
much earlier in life than is currently recommended.
It is important to note that our study is not a substitute
for a randomized trial. Although our study provides an
estimate of the potential risk reduction that can be achieved
with long-term exposure to lower LDL-C, it cannot esti-
mate the potential risks of long-term exposure to a lipid-
lowering therapy. Only a randomized trial can adequately
compare the benefits and risks of long-term exposure to a
lipid-lowering therapy.
Until such a long-term trial is conducted, however, the
results of our study suggest that an effective primary pre-
vention strategy may be to place greater emphasis on a
healthy diet and regular exercise beginning early in life, with
the aim of maintaining low levels of LDL-C. For persons
who cannot maintain a low level of LDL-C with diet and
exercise alone, it may be reasonable to consider adding a
treatment to lower LDL-C beginning in early adulthood,
before the development of significant atherosclerosis. A
primary prevention strategy that encourages maintaining
low levels of LDL-C throughout the whole of one’s
lifetime has the potential to dramatically reduce the risk
of CHD. In future, it may be possible to further
personalize this strategy by focusing more intensely on
persons who inherit 1 or more polymorphisms that
increase their vulnerability to LDL-C (41).
Study limitations. Our study has several limitations, in-
cluding inherent limitations with making causal inferences
using the principle of Mendelian randomization (6,42) and
the fact that we measured the associations of the included
SNPs with LDL-C and CHD, respectively, in different
populations. In addition, although our study relies on the
principle of Mendelian randomization, our use of summary
data did not allow us to perform an instrumental variables
analysis.
Recognizing these limitations in our study design, we
tested the assumptions of Mendelian randomization by
evaluating multiple different polymorphisms and assessing
for consistency of effect. We found no evidence of any
heterogeneity of effect on the risk of CHD per unit lower
LDL-C among any of the polymorphisms included in our
study. This lack of heterogeneity of effect strongly suggests
that the results of our study are unlikely to be significantly
confounded by pleiotropy or linkage disequilibrium because
it is unlikely that each of the included polymorphisms are
acting through similar pleiotropic effects or have similar
linkage disequilibrium patterns.
Indeed, the results of our study appear to have been
independently, although indirectly, confirmed in a recent
study evaluating the effect of polymorphisms that influence
HDL-C (43). In that study, a weighted LDL-C genetic
score including 13 polymorphisms associated with LDL-C
(only 2 of which overlapped with the polymorphism in-
cluded in our study) was associated with 2.13-fold increased
risk of MI (95% CI: 1.69 to 2.69) for each SD (34.1 mg/dl)
2638 Ference et al. JACC Vol. 60, No. 25, 2012
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reported in that study, the reciprocal of this estimate is 0.47
(95% CI: 0.37 to 0.59), representing a 53.0% proportional
reduction in risk per 34.1 mg/dl lower long-term exposure
to LDL-C. The magnitude of this effect agrees closely with
the results reported here and therefore provides external
validation of our study results.
Conclusions
In summary, we conducted a series of meta-analyses involv-
ing 9 polymorphisms in 6 different genes to reliably quantify
the effect of long-term exposure to lower LDL-C on the
risk of CHD. We found that prolonged exposure to lower
LDL-C beginning early in life is associated with a 3-fold
greater reduction in the risk of CHD for each unit lower
LDL-C than treatment with a statin started later in life and
that this effect appears to be independent of the mechanism
by which LDL-C is lowered.
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